Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.

Hirano, Ikuo; Dellon, Evan S; Hamilton, Jennifer D; Collins, Margaret H; Peterson, Kathryn; Chehade, Mirna; Schoepfer, Alain M; Safroneeva, Ekaterina; Rothenberg, Marc E; Falk, Gary W; Assouline-Dayan, Yehudith; Zhao, Qiong; Chen, Zhen; Swanson, Brian N; Pirozzi, Gianluca; Mannent, Leda; Graham, Neil M H; Akinlade, Bolanle; Stahl, Neil; Yancopoulos, George D; ... (2020). Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Gastroenterology, 158(1), pp. 111-122. Elsevier 10.1053/j.gastro.2019.09.042

1-s2.0-S0016508519414157-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (2MB) | Preview

BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin 4 (IL4) receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE. METHODS We performed a phase 2 study of adults with active EoE (2 dysphagia episodes of dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils per high-power field), from May 12, 2015 through November 9, 2016 at 14 sites. Subjects were randomly assigned to groups that received weekly subcutaneous injections of dupilumab (300 mg; n=23) or placebo (n=24) for 12 weeks. The primary endpoint was change from baseline to week 10 in Straumann dysphagia instrument patient-reported outcome (SDI-PRO) score. We also assessed histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic scores), endoscopically visualized features (endoscopic reference score), esophageal distensibility, and safety. RESULTS The mean SDI-PRO score was 6.4 when the study began. In the dupilumab group, SDI-PRO scores were reduced by a mean value of 3.0 at week 10 compared with vs a mean reduction of 1.3 in the placebo group (P=.0304) At week 12, dupilumab reduced peak esophageal intraepithelial eosinophil count by a mean 86.8 eosinophils per high-power field (reduction of 107.1%; P<.0001 compared with baseline), the EoE-HSS severity score by 68.3% (P<.0001 vs baseline), and the endoscopic reference score by 1.6 (P=.0006 compared with baseline. Dupilumab increased esophageal distensibility by 18% compared with baseline (P<.0001). Higher proportions of patients in the dupilumab group developed injection-site erythema (35% vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the placebo group). CONCLUSIONS In a phase 2 trial of patients with active EoE, dupilumab reduced dysphagia, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflammation), and abnormal endoscopic features, compared with placebo. Dupilumab increased esophageal distensibility and was generally well tolerated. ClinicalTrials.gov no: NCT02379052.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Safroneeva, Ekaterina


600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services








Andrea Flükiger-Flückiger

Date Deposited:

28 Oct 2019 15:22

Last Modified:

25 Feb 2020 15:20

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

EREFS HSS esophagus food allergy





Actions (login required)

Edit item Edit item
Provide Feedback